Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Microparticles for inhalational delivery of antipseudomonal antibiotics.

Tsifansky MD, Yeo Y, Evgenov OV, Bellas E, Benjamin J, Kohane DS.

AAPS J. 2008 Jun;10(2):254-60. doi: 10.1208/s12248-008-9033-8. Epub 2008 May 3.

2.

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Langton Hewer SC, Smyth AR.

Cochrane Database Syst Rev. 2014 Nov 10;(11):CD004197. doi: 10.1002/14651858.CD004197.pub4. Review. Update in: Cochrane Database Syst Rev. 2017 Apr 25;4:CD004197.

PMID:
25383937
3.

Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.

Antonela Antoniu S.

Expert Rev Anti Infect Ther. 2012 Dec;10(12):1439-46. doi: 10.1586/eri.12.136. Review.

PMID:
23253321
4.

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.

Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E; Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient.

Clin Microbiol Infect. 2005 Sep;11(9):690-703. Review.

5.

The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Banerjee D, Stableforth D.

Drugs. 2000 Nov;60(5):1053-64. Review.

PMID:
11129122
6.

Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

Geller DE, Weers J, Heuerding S.

J Aerosol Med Pulm Drug Deliv. 2011 Aug;24(4):175-82. doi: 10.1089/jamp.2010.0855. Epub 2011 Mar 11. Review.

7.

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Langton Hewer SC, Smyth AR.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004197. doi: 10.1002/14651858.CD004197.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;11:CD004197.

PMID:
19821321
8.

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

Ryan G, Jahnke N, Remmington T.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD008319. doi: 10.1002/14651858.CD008319.pub2. Review.

PMID:
23235659
9.

Oral anti-pseudomonal antibiotics for cystic fibrosis.

Remmington T, Jahnke N, Harkensee C.

Cochrane Database Syst Rev. 2016 Jul 14;7:CD005405. doi: 10.1002/14651858.CD005405.pub4. Review.

PMID:
27412131
10.

Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.

Serisier DJ.

Drugs Today (Barc). 2012 May;48(5):339-51. doi: 10.1358/dot.2012.48.5.1789474. Review.

PMID:
22645722
11.
12.

Aerosolized antibiotics in cystic fibrosis: an update.

Fiel SB.

Expert Rev Respir Med. 2014 Jun;8(3):305-14. doi: 10.1586/17476348.2014.896205. Review.

PMID:
24838090
13.

[Use of inhaled tobramycin in patients with cystic fibrosis].

Chermenskiĭ AG, Gembitskaia TE.

Ter Arkh. 2010;82(8):76-8. Review. Russian.

PMID:
20873251
14.

Oral anti-pseudomonal antibiotics for cystic fibrosis.

Remmington T, Jahnke N, Harkensee C.

Cochrane Database Syst Rev. 2013 Oct 29;(10):CD005405. doi: 10.1002/14651858.CD005405.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;7:CD005405.

PMID:
24170644
15.

Pseudomonas aeruginosa: resistance and therapy.

Cunha BA.

Semin Respir Infect. 2002 Sep;17(3):231-9. Review.

PMID:
12226802
16.

Oral anti-pseudomonal antibiotics for cystic fibrosis.

Remmington T, Jahnke N, Harkensee C.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005405. Review. Update in: Cochrane Database Syst Rev. 2013;10:CD005405.

PMID:
17636796
17.

Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand?

Klinger-Strobel M, Lautenschläger C, Fischer D, Mainz JG, Bruns T, Tuchscherr L, Pletz MW, Makarewicz O.

Expert Opin Drug Deliv. 2015 Aug;12(8):1351-74. doi: 10.1517/17425247.2015.1007949. Epub 2015 Feb 2. Review.

PMID:
25642831
18.

The role of nebulized antibiotics in treating serious respiratory infections.

Cole PJ.

J Chemother. 2001 Aug;13(4):354-62. Review.

PMID:
11589477

Supplemental Content

Support Center